The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Rana Abdelnabi, Caroline S Foo, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Raf Mols, Birgit Weynand, Thanaporn Wattanakul, Richard M Hoglund, Joel Tarning, Charles E Mowbray, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain, Johan Neyts
doi:10.1101/2021.11.04.467077
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.
Ethics Housing conditions and experimental procedures were done with the approval and under the guidelines of the ethics committee of animal experimentation of KU Leuven (license P065-2020).
Conflict of interest
None to declare
Author
References
Abdelnabi, Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters, EBioMedicine
Abdelnabi, Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model, J. Infect. Dis
Abdelnabi, The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model, EBioMedicine
Boras, Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19, bioRxiv,
doi:10.1101/2020.09.12.293498Boudewijns, STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters, Nat. Commun
Chen, Liu, Guo, Emerging coronaviruses: Genome structure, replication, and pathogenesis, Journal of Medical Virology
Do, A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents, Antiviral Res
Fan, The substrate specificity of SARS coronavirus 3C-like proteinase, Biochem. Biophys. Res. Commun
Ivens, Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus, J. Virol. Methods
Jin, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature
Jochmans, Leyssen, Neyts, A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE, J. Virol. Methods
Kabinger, Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat. Struct. Mol. Biol
Kaptein, Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity, Proc. Natl. Acad. Sci. U. S. A
Keizer, Van Benten, Beijnen, Schellens, Huitema, Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM, Comput. Methods Programs Biomed
Kokic, Mechanism of SARS-CoV-2 polymerase stalling by remdesivir, Nat. Commun
Lindbom, Ribbing, Jonsson, Perl-speaks-NONMEM (PsN) -A Perl module for NONMEM related programming, Comput. Methods Programs Biomed
Pillaiyar, Manickam, Namasivayam, Hayashi, Jung, An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy, Journal of Medicinal Chemistry
Schäfer, Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice, bioRxiv : the preprint server for biology,
doi:10.1101/2021.09.13.460111Ullrich, Nitsche, The SARS-CoV-2 main protease as drug target, Bioorganic and Medicinal Chemistry Letters
DOI record:
{
"DOI": "10.1101/2021.11.04.467077",
"URL": "http://dx.doi.org/10.1101/2021.11.04.467077",
"abstract": "<jats:title>Abstract</jats:title><jats:p>There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent <jats:italic>in vitro</jats:italic> activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.</jats:p>",
"accepted": {
"date-parts": [
[
2021,
11,
5
]
]
},
"author": [
{
"affiliation": [],
"family": "Abdelnabi",
"given": "Rana",
"sequence": "first"
},
{
"affiliation": [],
"family": "Foo",
"given": "Caroline S.",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-9265-6028",
"affiliation": [],
"authenticated-orcid": false,
"family": "Jochmans",
"given": "Dirk",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Vangeel",
"given": "Laura",
"sequence": "additional"
},
{
"affiliation": [],
"family": "De Jonghe",
"given": "Steven",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Augustijns",
"given": "Patrick",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mols",
"given": "Raf",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Weynand",
"given": "Birgit",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wattanakul",
"given": "Thanaporn",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hoglund",
"given": "Richard M.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tarning",
"given": "Joel",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mowbray",
"given": "Charles E.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Sjö",
"given": "Peter",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Escudié",
"given": "Fanny",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Scandale",
"given": "Ivan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Chatelain",
"given": "Eric",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Neyts",
"given": "Johan",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
11,
5
]
],
"date-time": "2021-11-05T22:15:12Z",
"timestamp": 1636150512000
},
"deposited": {
"date-parts": [
[
2022,
5,
25
]
],
"date-time": "2022-05-25T19:50:24Z",
"timestamp": 1653508224000
},
"group-title": "Microbiology",
"indexed": {
"date-parts": [
[
2024,
3,
2
]
],
"date-time": "2024-03-02T00:24:36Z",
"timestamp": 1709339076428
},
"institution": [
{
"name": "bioRxiv"
}
],
"is-referenced-by-count": 6,
"issued": {
"date-parts": [
[
2021,
11,
5
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2021.11.04.467077",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2021,
11,
5
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2021,
11,
5
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference": [
{
"DOI": "10.1002/jmv.25681",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.1"
},
{
"DOI": "10.1038/s41586-020-2223-y",
"article-title": "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors",
"doi-asserted-by": "crossref",
"first-page": "289",
"journal-title": "Nature",
"key": "2021110905200473000_2021.11.04.467077v1.2",
"volume": "582",
"year": "2020"
},
{
"DOI": "10.1021/acs.jmedchem.5b01461",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.3"
},
{
"DOI": "10.1016/j.bbrc.2005.02.061",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.4"
},
{
"DOI": "10.1016/j.bmcl.2020.127377",
"doi-asserted-by": "crossref",
"key": "2021110905200473000_2021.11.04.467077v1.5",
"unstructured": "Ullrich, S. & Nitsche, C. The SARS-CoV-2 main protease as drug target. Bioorganic and Medicinal Chemistry Letters 30, (2020)."
},
{
"DOI": "10.1101/2020.09.12.293498",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.6"
},
{
"DOI": "10.1126/science.abl4784",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.7"
},
{
"DOI": "10.1016/j.antiviral.2021.105122",
"doi-asserted-by": "crossref",
"key": "2021110905200473000_2021.11.04.467077v1.8",
"unstructured": "Do, T. N. D. et al. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. Antiviral Res. 192, (2021)."
},
{
"author": "Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment",
"first-page": "6",
"journal-title": "Press Announcements",
"key": "2021110905200473000_2021.11.04.467077v1.9",
"volume": "3",
"year": "2020"
},
{
"DOI": "10.1038/s41467-020-20542-0",
"doi-asserted-by": "crossref",
"key": "2021110905200473000_2021.11.04.467077v1.10",
"unstructured": "Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 12, (2021)."
},
{
"DOI": "10.1101/2021.09.13.460111",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.11"
},
{
"DOI": "10.1038/s41594-021-00651-0",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.12"
},
{
"DOI": "10.1016/j.ebiom.2021.103595",
"doi-asserted-by": "crossref",
"key": "2021110905200473000_2021.11.04.467077v1.13",
"unstructured": "Abdelnabi, R. et al. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine 72, (2021)."
},
{
"DOI": "10.1093/infdis/jiab361",
"article-title": "Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model",
"doi-asserted-by": "crossref",
"first-page": "749",
"journal-title": "J. Infect. Dis",
"key": "2021110905200473000_2021.11.04.467077v1.14",
"volume": "224",
"year": "2021"
},
{
"DOI": "10.1073/pnas.2014441117",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.15"
},
{
"DOI": "10.1016/j.ebiom.2021.103403",
"article-title": "Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters",
"doi-asserted-by": "crossref",
"first-page": "103403",
"journal-title": "EBioMedicine",
"key": "2021110905200473000_2021.11.04.467077v1.16",
"volume": "68",
"year": "2021"
},
{
"DOI": "10.1016/j.jviromet.2005.05.010",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.17"
},
{
"DOI": "10.1016/j.jviromet.2012.04.011",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.18"
},
{
"DOI": "10.1038/s41467-020-19684-y",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.19"
},
{
"DOI": "10.1016/j.cmpb.2003.11.003",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.20"
},
{
"DOI": "10.1016/j.cmpb.2010.04.018",
"doi-asserted-by": "publisher",
"key": "2021110905200473000_2021.11.04.467077v1.21"
}
],
"reference-count": 21,
"references-count": 21,
"relation": {
"is-preprint-of": [
{
"asserted-by": "subject",
"id": "10.1038/s41467-022-28354-0",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "http://biorxiv.org/lookup/doi/10.1101/2021.11.04.467077"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"subtype": "preprint",
"title": "The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern",
"type": "posted-content"
}
